Evidence map›Paper›PMID 28195515›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2017

Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis.

Khosrow Khodabandehlou, Jacqueline J Masehi-Lano, Christopher Poon, Jonathan Wang, Eun Ji Chung

Open access · greenAbstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Vascular mechanotransduction.Physiological reviews · 2023
    Review
  13. Article
  14. Article
  15. Anti‑βInternational journal of molecular medicine · 2022
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Khosrow KhodabandehlouDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Jacqueline J Masehi-LanoDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Christopher PoonDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Jonathan WangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Eun Ji ChungDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
University of Southern California · US

Funding

Multimodal Peptide Amphiphile Micelles for AtherosclerosisR00HL124279 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2016 to 2018
$747k
NHLBI NIH HHS R00 HL124279
6 · The paper itself

Abstract

Atherosclerosis is a leading cause of death worldwide; in addition to lipid dysfunction, chronic arterial wall inflammation is a key component of atherosclerosis. Techniques that target cell adhesion molecules, which are overexpressed during inflammation, are effective methods to detect and treat atherosclerosis. Specifically, research groups have identified vascular cell adhesion molecule-1, intercellular adhesion molecule-1, platelet endothelial cell adhesion molecule, and selectins (E-selectin and P-selectin) as correlated to atherogenesis. In this review, we discuss recent strategies both in vivo and in vitro that target cell adhesion molecules. First, we discuss peptide-based and antibody (Ab)-based nanoparticles utilized in vivo for diagnostic, therapeutic, and theranostic applications. Second, we discuss flow-based in vitro models that serve to reduce the traditional disadvantages of in vivo studies such as variability, time to develop the disease, and ethical burden, but preserve physiological relevance. The knowledge gained from these targeting studies can be translated into clinical solutions for improved detection, prevention, and treatment of atherosclerosis. Impact statement As atherosclerosis remains the leading cause of death, there is an urgent need to develop better tools for treatment of the disease. The ability to improve current treatments relies on enhancing the accuracy of in vitro and in vivo atherosclerotic models. While in vivo models provide all the relevant testing parameters, variability between animals and among models used is a barrier to reproducible results and comparability of NP efficacy. In vitro cultures isolate cells into microenvironments that fail to take into account flow separation and shear stress, which are characteristics of atherosclerotic lesions. Flow-based in vitro models provide more physiologically relevant platforms, bridging the gap between in vivo and 2D in vitro models. This is the first review that presents recent advances regarding endothelial cell-targeting using adhesion molecules in light of in vivo and flow-based in vitro models, providing insights for future development of optimal strategies against atherosclerosis.

Indexed as

AnimalsAtherosclerosisCell AdhesionCell Adhesion MoleculesEndothelial CellsMiceNanoparticlesCell Adhesion MoleculesatherosclerosisCell adhesion moleculesendothelial cellsflow-based modelsnanoparticlestargeting

Identifiers

PMID28195515
PMCPMC5407539
OpenAlexW2588661461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.